US biotech companies Sage Therapeutics (Nasdaq: SAGE) and Biogen (Nasdaq: BIIB) have announced that the CORAL study in people with major depressive disorder (MDD) met the trial objectives.
This was achieved by the drug’s use alongside an open-label standard of care antidepressant (ADT) demonstrating a rapid and statistically-significant reduction in depressive symptoms at day three and over the two-week treatment period, achieving the primary and key secondary endpoints.
The companies focused on the positives from the trial findings, ignoring questions over the long-term effect of zuranolone, which has been doubted by investors in the past.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze